Clinical Trial Update: Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial results show vandetanib was evaluated for safety and tolerability in Japanese patients with unresectable locally advanced or metastatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Vandetanib (vandetanib)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Unresectable Locally Advanced or Metastatic, Medullary Thyroid Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-05-19